A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function
Phase 1
33
about 9 months
18–85
3 sites in FL, TX
What this study is about
Researchers are testing how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The trial will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lepodisiran
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: PK: Maximum Concentration (Cmax) of Lepodisiran, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Lepodisiran
Gastroenterology